While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.